Introduction
Spontaneous uterine rupture in the first trimester is a redoubtable obstetric emergency that carries a high risk for both mother and fetus.
Cases presentation
We present the case of a spontaneous uterine rupture in a patient with a scarred uterus at 9 weeks' gestation treated by laparotomy in emergency obstetrical department of Ibn Rochd University Hospital of Casablanca; whose histological examination of the removed material found a partial mole.
Clinical discussion
Spontaneous uterine rupture in the first trimester is rare and usually occurs in a scarred or malformed uterus. Clinicians should consider this diagnosis in the presence of an acute abdominal pain in early pregnancy with or without first trimester metrorrhagia.
Conclusion
Since the rate of uterine surgeries is increasing, it is necessary to highlight the risk of uterine rupture occurring early in order to improve their management. Molar pregnancy is a factor of fragility of the uterine wall and uterine rupture must be suspected in any molar pregnancy associated with a hemoperitoneum.
Introduction:
Primary cancers of the uterine tube are among the rare tumors of the female genital tract, representing less than 2% of gynecologic malignancies.
Cases presentation:
We report a case of tubal adenocarcinoma diagnosed incidentally on a hysterectomy specimen in a patient followed at the gynecology department. The patient underwent primary reduction surgery followed by six courses of adjuvant chemotherapy with carboplatin and paclitaxel combined with 23 sessions of radiotherapy and two courses of brachytherapy. The patient is in complete remission with a follow-up of 14 months.
Clinical discussion:
These cancers of unknown etiology are dominated by adenocarcinoma, the clinical signs are often dissociated, and the preoperative diagnosis is difficult. The diagnosis should be made in the presence of any metrorrhagia associated with leucorrhoea in postmenopausal women. The treatment is similar to that of malignant epithelial tumors of the ovary with a prognosis that depends on the stage of the disease.
Conclusion:
The diagnosis of cancers of the uterine tube is very difficult to confirm because of the proximity of the uterus and the ovary and to evoke in front of any cellular atypia of the cervico-uterine smear associated with adnexal anomalies.
Highlights
Introduction
Primary non-Hodgkin's malignant lymphoma (NHML) of the uterine body is an extremely rare localization since only eleven cases have been reported in the literature.
Case presentation
We report a case of primary NHML of the uterine body discovered during a hysterectomy performed for a uterine mass. The primary character of NHML of the uterine body was retained in view of the absence of extra-genital localization in the clinical, biological and radiological workup (Ann Arbor stage IE) and there were no signs of recurrence during follow-up. The patient received anti-CD20 immunochemotherapy (rituximab-CHOP and rituximab-VCAP combinations) and at 12 months follow-up, she is in complete remission.
Discussion
The diagnosis of primary and isolated NHML of the uterine body is based on a clinical and further examination and regular follow-up for several months. The treatment is not codified; surgery, poly-chemotherapy and radiotherapy are the different therapeutic modalities. Rituximab-CHOP immunochemotherapy is currently the reference treatment for primary malignant lymphomas of the uterine body particularly in young patients who wish to become pregnant. The prognosis depends mainly on two factors: age and Ann Arbor stage.
Conclusion
Primary uterine lymphomas are rare tumors of unknown etiopathogeny and of non-specific clinical presentation, the role of the various treatments remains difficult to evaluate due to the small number of published cases.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.